Phase I Brachytherapy Dose Escalation Using The GliaSite RTS In Newly Diagnosed Glioblastoma Multiforme In Conjunction With External Beam Radiation Therapy
- Determine the maximum tolerated dose of brachytherapy administered via GliaSite RTS™
applicator followed by external beam radiotherapy in patients with newly diagnosed
- Determine the acute and chronic toxicity of brachytherapy administered via GliaSite
RTS™ in these patients.
- Determine the survival rate of patients treated with this regimen.
OUTLINE: This is a multicenter, dose-escalation study of brachytherapy.
Patients undergo craniotomy for histologic confirmation of glioblastoma multiforme, surgical
resection, and placement of a GliaSite RTS™ applicator that includes Iotrex™.
Beginning 3-21 days after surgery, patients undergo brachytherapy via the GliaSite RTS™
applicator. Within 30 days of brachytherapy (no more than 60 days after resection) patients
undergo external beam radiotherapy 5 days a week for 6 weeks in the absence of disease
progression or unacceptable toxicity.
Cohorts of 5-10 patients receive escalating doses of brachytherapy until the maximum
tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which
at least 2 of 5 or 3 of 10 patients experience dose-limiting toxicity.
Patients are followed at 21-35 days, every 2 months for 1 year, and then for survival.
PROJECTED ACCRUAL: A total of 15-100 patients will be accrued for this study.
Primary Purpose: Treatment
Volker W. Stieber, MD
Comprehensive Cancer Center of Wake Forest University
United States: Federal Government
|H. Lee Moffitt Cancer Center and Research Institute
|Tampa, Florida 33612
|University of Texas Health Science Center at San Antonio
|San Antonio, Texas 78284-7811
|Massachusetts General Hospital Cancer Center
|Boston, Massachusetts 02114
|University of Alabama at Birmingham Comprehensive Cancer Center
|Birmingham, Alabama 35294-3300
|Comprehensive Cancer Center at Wake Forest University
|Winston-Salem, North Carolina 27157-1082
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
|Baltimore, Maryland 21231-2410
|Cleveland Clinic Taussig Cancer Center
|Cleveland, Ohio 44195
|Josephine Ford Cancer Center at Henry Ford Hospital
|Detroit, Michigan 48202
|Winship Cancer Institute of Emory University
|Atlanta, Georgia 30322
|Abramson Cancer Center at University of Pennsylvania Medical Center
|Philadelphia, Pennsylvania 19104